HER-2 therapy. HER-2/neu diagnostics in breast cancer

Walter P. Carney, Kim Leitzel, Suhail Ali, Rainer Neumann, Allan Lipton

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

HER-2/neu status of the primary breast cancer (PBC) is determined by immunohistochemistry and fluorescent in situ hybridization. Because of a variety of technical factors, however, the PBC may not accurately reflect the metastatic tumor in terms of HER-2/neu status. Recently published guidelines recommend that tumors be defined as HER-2/neu positive if 30% or more of the cells are 3+. Circulating levels of the HER-2 extracellular domain can be measured in serum using a test cleared by the US Food and Drug Administration, and increased serum HER-2/neu levels to above 15 ng/ml can reflect tumor progression. Studies comparing tissue HER-2/neu status of the PBC and HER-2/neu levels above 15 ng/ml in metastatic breast cancer patients are also reviewed.

Original languageEnglish (US)
Article number207
JournalBreast Cancer Research
Volume9
Issue number3
DOIs
StatePublished - Jun 4 2007

Fingerprint

Breast Neoplasms
Neoplasms
United States Food and Drug Administration
Therapeutics
Serum
Fluorescence In Situ Hybridization
Immunohistochemistry
Guidelines

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Carney, Walter P. ; Leitzel, Kim ; Ali, Suhail ; Neumann, Rainer ; Lipton, Allan. / HER-2 therapy. HER-2/neu diagnostics in breast cancer. In: Breast Cancer Research. 2007 ; Vol. 9, No. 3.
@article{c510df022a9d4393bc64dc9f44668b2b,
title = "HER-2 therapy. HER-2/neu diagnostics in breast cancer",
abstract = "HER-2/neu status of the primary breast cancer (PBC) is determined by immunohistochemistry and fluorescent in situ hybridization. Because of a variety of technical factors, however, the PBC may not accurately reflect the metastatic tumor in terms of HER-2/neu status. Recently published guidelines recommend that tumors be defined as HER-2/neu positive if 30{\%} or more of the cells are 3+. Circulating levels of the HER-2 extracellular domain can be measured in serum using a test cleared by the US Food and Drug Administration, and increased serum HER-2/neu levels to above 15 ng/ml can reflect tumor progression. Studies comparing tissue HER-2/neu status of the PBC and HER-2/neu levels above 15 ng/ml in metastatic breast cancer patients are also reviewed.",
author = "Carney, {Walter P.} and Kim Leitzel and Suhail Ali and Rainer Neumann and Allan Lipton",
year = "2007",
month = "6",
day = "4",
doi = "10.1186/bcr1664",
language = "English (US)",
volume = "9",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "3",

}

HER-2 therapy. HER-2/neu diagnostics in breast cancer. / Carney, Walter P.; Leitzel, Kim; Ali, Suhail; Neumann, Rainer; Lipton, Allan.

In: Breast Cancer Research, Vol. 9, No. 3, 207, 04.06.2007.

Research output: Contribution to journalReview article

TY - JOUR

T1 - HER-2 therapy. HER-2/neu diagnostics in breast cancer

AU - Carney, Walter P.

AU - Leitzel, Kim

AU - Ali, Suhail

AU - Neumann, Rainer

AU - Lipton, Allan

PY - 2007/6/4

Y1 - 2007/6/4

N2 - HER-2/neu status of the primary breast cancer (PBC) is determined by immunohistochemistry and fluorescent in situ hybridization. Because of a variety of technical factors, however, the PBC may not accurately reflect the metastatic tumor in terms of HER-2/neu status. Recently published guidelines recommend that tumors be defined as HER-2/neu positive if 30% or more of the cells are 3+. Circulating levels of the HER-2 extracellular domain can be measured in serum using a test cleared by the US Food and Drug Administration, and increased serum HER-2/neu levels to above 15 ng/ml can reflect tumor progression. Studies comparing tissue HER-2/neu status of the PBC and HER-2/neu levels above 15 ng/ml in metastatic breast cancer patients are also reviewed.

AB - HER-2/neu status of the primary breast cancer (PBC) is determined by immunohistochemistry and fluorescent in situ hybridization. Because of a variety of technical factors, however, the PBC may not accurately reflect the metastatic tumor in terms of HER-2/neu status. Recently published guidelines recommend that tumors be defined as HER-2/neu positive if 30% or more of the cells are 3+. Circulating levels of the HER-2 extracellular domain can be measured in serum using a test cleared by the US Food and Drug Administration, and increased serum HER-2/neu levels to above 15 ng/ml can reflect tumor progression. Studies comparing tissue HER-2/neu status of the PBC and HER-2/neu levels above 15 ng/ml in metastatic breast cancer patients are also reviewed.

UR - http://www.scopus.com/inward/record.url?scp=34548562456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548562456&partnerID=8YFLogxK

U2 - 10.1186/bcr1664

DO - 10.1186/bcr1664

M3 - Review article

VL - 9

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 3

M1 - 207

ER -